Chagas disease: pushing through the pipeline.
Clayton
Julie
J
D000328:Adult; D000818:Animals; D014355:Chagas Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D002648:Child; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical / Q000639:trends*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D058990:Molecular Targeted Therapy / Q000639:trends; D009593:Nitroimidazoles / Q000627:therapeutic use; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D014349:Trypanosoma cruzi / Q000187:drug effects / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D055815:Young Adult
D009593:Nitroimidazoles; D014230:Triazoles; D014344:Trypanocidal Agents; C101425:posaconazole; C009999:benzonidazole